Literature DB >> 6394341

The role of A-O-incompatible blood transfusions in porcine orthotopic liver transplantations.

M A Hunfeld, H F Hoitsma, S Meijer, H van Haeringen, F W Rietveld.   

Abstract

The consequences of administrations of A-O-incompatible blood transfusions during porcine orthotopic liver transplantations (OLT) are described. Two series, both subjected to the same standard procedure except for the administration of compatible or incompatible blood, are compared. The striking differences in peroperative and direct post-operative morbidity, mortality, and causes of death between the two series are presented. Although not generally applied, blood transfusions in experimental surgery should undergo the same precautionary measures as blood transfusions in humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6394341     DOI: 10.1159/000128432

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  3 in total

1.  Random allogeneic blood transfusion in pigs: characterisation of a novel experimental model.

Authors:  Alexander Ziebart; Moritz M Schaefer; Rainer Thomas; Jens Kamuf; Andreas Garcia-Bardon; Christian Möllmann; Robert Ruemmler; Florian Heid; Arno Schad; Erik K Hartmann
Journal:  PeerJ       Date:  2019-08-16       Impact factor: 2.984

2.  Improved Normothermic Machine Perfusion After Short Oxygenated Hypothermic Machine Perfusion of Ischemically Injured Porcine Kidneys.

Authors:  Stina Lignell; Stine Lohmann; Kaithlyn M Rozenberg; Henri G D Leuvenink; Merel B F Pool; Kate R Lewis; Cyril Moers; James P Hunter; Rutger J Ploeg; Marco Eijken; Ulla Møldrup; Søren Krag; Carla C Baan; Bjarne Kuno Møller; Anna Krarup Keller; Bente Jespersen
Journal:  Transplant Direct       Date:  2021-01-15

3.  Normothermic machine perfusion of ischaemically damaged porcine kidneys with autologous, allogeneic porcine and human red blood cells.

Authors:  Merel B F Pool; Loes Hartveld; Henri G D Leuvenink; Cyril Moers
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.